The tweet was deleted by the author.
But we saved everything 🙂.
Esperion Therapeutics will present two new analyses from its CLEAR Outcomes Clinical Trial at the American College of Cardiology 2026 Annual Scientific Session.
The company aims to showcase the latest research on cardiovascular therapies, underscoring continued innovation in cholesterol management and heart disease treatment. Details on the new trial results are expected to provide further insights into the efficacy and safety of Esperion Therapeutics' therapies.
The forthcoming data presentations further illustrate Esperion Therapeutics’ commitment to advancing cardiovascular care, building on momentum from its expansion of the cardiovascular portfolio through the acquisition of Corstasis Therapeutics and the addition of the Enbumyst nasal spray. More on the company’s evolving strategy can be found in detailed coverage of the Corstasis acquisition and its implications for Esperion’s therapeutic pipeline.